Navigation Links
Simeprevir Administered Once Daily as Part of Combination Therapy Demonstrates Sustained Virologic Response in Treatment-Naive and Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
Date:11/2/2013

WASHINGTON, Nov. 2, 2013 /PRNewswire/ -- Janssen R&D Ireland (Janssen) today announced the presentation of new data at The Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington, DC for the investigational protease inhibitor simeprevir (TMC435) in the treatment of genotype 1 chronic hepatitis C in treatment-naive and treatment-experienced adult patients with compensated liver disease. In analyses of the Phase 3 QUEST-1 and QUEST-2 studies in treatment-naive patients and the Phase 3 PROMISE study in prior relapse patients, the efficacy of simeprevir was observed in hepatitis C patients, including patients with the IL28B TT genotype and METAVIR scores of F4.

"Patients with certain baseline characteristics can be more likely to fail or relapse after prior treatment," said Ira Jacobson, M.D., simeprevir clinical trial investigator, chief of the Division of Gastroenterology and Hepatology, Vincent Astor Distinguished Professor of Medicine, Weill Cornell Medical College, and attending physician, New York-Presbyterian Hospital/Weill Cornell Medical Center. "The breadth of simeprevir data presented at AASLD reinforce its potential as a treatment option for patients and will offer important guidance to physicians once simeprevir is approved."   

On October 24, the U.S. Antiviral Drugs Advisory Committee of the FDA voted unanimously (19-0) to recommend approval of the new drug application filed by Janssen Research & Development, LLC for simeprevir administered once daily with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C virus (HCV) in adult patients with compensated liver disease.

Pooled Analysis from QUEST-1 and QUEST-2 Confirms Clinical Benefit of Simeprevir in Sub-Populations of Patients (Abstract 1122)        
'/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Simeprevir Data in Hepatitis C Patients to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
2. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
3. U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
4. Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
5. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
6. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
7. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
8. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
9. MCOs Shifting Control Over Office-Administered Products from Medical to Pharmacy Benefit, Particularly Affecting Rheumatoid Arthritis Therapies
10. American Journal of Medicine Publishes Hypertension Study Comparing the Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone versus Azilsartan Medoxomil Co-administered with Hydrochlorothiazide
11. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)...  The board of directors of VirtualScopics, Inc. (NASDAQ: ... trial imaging solutions, today announced that James Groff ... immediately.  Mr. Groff has held the role of acting ... in January 2006 as an accounting manager and was ... the board of VirtualScopics asked Jim to assume the ...
(Date:8/21/2014)... 21, 2014  SI-BONE, Inc. ( San Jose, ... the use of the iFuse Implant System, ® ... of the sacroiliac (SI) joint, announced that Priority Health ... its Lumbar Fusion Medical Policy No. 91590-R4 providing positive ... policy states that the fusion procedure, which employs the ...
(Date:8/20/2014)... 2014  The National Association of Drug Diversion ... by the real-time, pseudoephedrine (PSE) blocking system in ... Exchange (NPLEx), automatically blocks unlawful PSE sales and ... and make arrests. Data released by NPLEx shows ... blocked the sale of more than 23,478 boxes of ...
Breaking Medicine Technology:VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3Kentucky's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... 2011 As the Joint Select Committee on Deficit Reduction ... the next ten years, the Pharmaceutical Care Management Association ... committee opportunities to leverage greater use of pharmacy benefit management ... costs over that same time period. "Everyone in ...
... Aug. 31, 2011 LifeVantage Corporation (OTCBB: ... supplement, announced today that Douglas C. Robinson, the Company,s ... the Company,s Chief Science Officer, will be presenting at ... be held on September 11-13, 2011, at the Waldorf ...
Cached Medicine Technology:PCMA Outlines $100 Billion in Prescription Drug Savings for Deficit Reduction Committee 2PCMA Outlines $100 Billion in Prescription Drug Savings for Deficit Reduction Committee 3LifeVantage to Present at Rodman & Renshaw Annual Global Investment Conference 2
(Date:8/21/2014)... San Diego, CA (PRWEB) August 21, 2014 ... this year, is a short but powerful collection of ... meant to uplift and inspire other budding entrepreneurs on ... honored and proud to announce the inclusion of President ... and insight from highly successful and self-made celebrities such ...
(Date:8/21/2014)... ERT, a leading global solution ... endpoint data collection, today opened registration for ... Product Value with Optimized Endpoints. The ... developers to network with leading researchers as ... implementing, and justifying effective strategies for collecting ...
(Date:8/21/2014)... Early diagnosis of diabetic peripheral neuropathy is important ... group at the Fourth Affiliated Hospital of Kunming ... sought to establish a sensitive index for nerve ... neuropathy in 500 patients with diabetes mellitus. Nerve ... longer, sensory nerve conduction velocity was slower, and ...
(Date:8/21/2014)... 21, 2014 The ... Vascular Devices Market by Angioplasty Balloon ... (IVUS, OCT), IVC Filter (Retrievable), Endovascular ... analyzes and studies the major market ... U.S. and Canada. , Browse 108 ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Artisan Business ... & Investment Exploratory Delegation to southern China October 12-19, ... to explore the rapid growing cities of Shenzhen and ... will have the rare opportunity to meet with major ... during a short weeklong time frame. , The ...
Breaking Medicine News(10 mins):Health News:Earth Source Organics President Audrey Darrow Featured in New David Mullings Book 2Health News:ERT Opens Registration for PROFICIENCY™ Regional Conference Series 2Health News:ERT Opens Registration for PROFICIENCY™ Regional Conference Series 3Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 2Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 3Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 4Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 5Health News:Artisan Business Group announces 2014 EB-5 Investment Trade Mission to China 2
... June 5 (HealthDay News) -- The human body has two ... and the "good" brown kind that burns them. Now, researchers ... fat to help people lose weight. "We are now ... treating obesity and diabetes," study lead author Dr. Aaron Cypess, ...
... -- ASCO Abstract #CRA9015. Flaxseed provides no benefit in ... and postmenopausal women, according to a Mayo Clinic ... (NCCTG) study. The randomized, placebo-controlled study was conducted on ... no statistically significant difference in mean hot flash scores ...
... a study that included nearly 18,000 children who had cancer, ... associated with a subsequent primary neoplasm (a new tumor) at ... neoplasms (related to the genital or urinary tract organs), according ... JAMA , a theme issue on cancer. The study is ...
... a woman,s skin wrinkles are during the first few years ... will be presented Monday at The Endocrine Society,s 93rd Annual ... the skin may offer a glimpse of the skeletal well-being, ... reproductive endocrinologist and associate professor at Yale School of Medicine, ...
... HealthDay Reporter , FRIDAY, June 3 (HealthDay News) -- U.S. ... little chance the deadly new strain of E. coli bacteria ... impact here. "This outbreak has not affected the ... Administration,s Regional Operations, said during a Friday afternoon news conference. ...
... -- A mutant gene long thought to accelerate tumor ... of malignant cells, showing promise for novel cancer therapies, ... will be presented by Mayo Clinic researcher Honey Reddi, ... Dr. Reddi,s discovery could have widespread implications in cancer ...
Cached Medicine News:Health News:Brown Fat Cells May One Day Help Combat Obesity 2Health News:Mayo Clinic: Flaxseed no cure for hot flashes during breast cancer or menopause 2Health News:Childhood cancer survivors at increased risk of certain tumors in middle-age 2Health News:Childhood cancer survivors at increased risk of certain tumors in middle-age 3Health News:Severity of facial wrinkles may predict bone density in early menopause 2Health News:Officials: U.S. Not Affected by European E. Coli Outbreak 2Health News:Officials: U.S. Not Affected by European E. Coli Outbreak 3Health News:Fighting cancer with cancer: Mayo Clinic finds promising use for thyroid cancer gene 2
... The Portex® Thermovent® T helps provide protection ... It is small and extremely lightweight making it ... adults. With a high rate of heat and ... secretion retention., ,All HMEs and filters have ...
circuitGuard™ Products are available in filter or filter/HME styles., ,High quality air cushion anesthesia masks may be packaged with any circuitGuard™ product....
... Since 1991 Intersurgical Incorporated ... filters, heat and moisture ... therapy products, hand-held nebulizers ... of accessories and connectors ...
... 1991 Intersurgical Incorporated manufactures ... heat and moisture exchangers, ... products, hand-held nebulizers and ... accessories and connectors for ...
Medicine Products: